The median expression value of serum exo-AnxA2 in breast cancer patients (n = 107) was used for DFS evaluation and stratified into high exo-AnxA2 (> 70.87 ng/mL) and low exo-AnxA2 groups (< 70.87 ng/mL). The gene discussed is ANXA2; the disease is breast carcinoma.